This database contains 222 studies, archived under the term: "cognition disorders"
Click here to filter this large number of results.
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
Green, Robert C.,
Schneider, Lon S.,
Amato, David A.,
Beelen, Andrew P.,
Wilcock, Gordon,
Swabb, Edward A.,
Zavitz, Kenton H.
Context: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.; Objective: To determine the efficacy, safety, and tolerability of tarenflurbil.; Design, Setting, and Patients: A multicenter, randomized, double-blind, […]
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach
Ferris, Steven,
Lane, Roger,
Sfikas, Nikolaos,
Winblad, Bengt,
Farlow, Martin,
Feldman, Howard H.
Background: Epidemiologic studies have identified several demographic factors, including gender, that may influence the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD).; Objective: This analysis aimed to develop a sensitive model for detecting treatment benefits in patients with MCI by controlling for factors that predict progression to AD. The study used this statistical […]
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
Doody, R. S.,
Ferris, S. H.,
Salloway, S.,
Sun, Y.,
Goldman, R.,
Watkins, W. E.,
Xu, Y.,
Murthy, A. K.
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change […]
A pilot study using nabilone for symptomatic treatment in Huntington’s disease
Pilot study of nabilone in Huntington’s disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Huntington’s Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = […]
An exploratory cluster randomized controlled trial of group exercise on mobility and depression in care home residents
Brittle, Nicola,
Patel, Smitaa,
Wright, Christine,
Baral, Sabrina,
Versfeld, Pam,
Sackley, Catherine
Objective: To investigate the feasibility, acceptability and potential efficacy of group exercise for residents in care homes.; Design: Exploratory cluster randomized controlled trial.; Setting: Five randomly selected care homes in South Birmingham, UK.; Participants: Fifty-six care home residents (mean age 84.5, 71% female), 39 (70%) with cognitive impairments.; Intervention: Two homes (n = 28) were […]
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study
Bokde, Arun L. W.,
Karmann, Michaela,
Teipel, Stefan J.,
Born, Christine,
Lieb, Martin,
Reiser, Maximilian F.,
Möller, Hans-Jürgen,
Hampel, Harald
Visual perception has been shown to be altered in Alzheimer disease (AD) patients, and it is associated with decreased cognitive function. Galantamine is an active cholinergic agent, which has been shown to lead to improved cognition in mild to moderate AD patients. This study examined brain activation in a group of mild AD patients after […]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease
Beglinger, Leigh J.,
Adams, Williams H.,
Paulson, Henry,
Fiedorowicz, Jess G.,
Langbehn, Douglas R.,
Duff, Kevin,
Leserman, Anne,
Paulsen, Jane S.
Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive […]
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial
Barnes, Deborah E.,
Yaffe, Kristine,
Belfor, Nataliya,
Jagust, William J.,
DeCarli, Charles,
Reed, Bruce R.,
Kramer, Joel H.
We performed a pilot randomized, controlled trial of intensive, computer-based cognitive training in 47 subjects with mild cognitive impairment. The intervention group performed exercises specifically designed to improve auditory processing speed and accuracy for 100 min/d, 5 d/wk for 6 weeks; the control group performed more passive computer activities (reading, listening, visuospatial game) for similar […]
Cognitive decline from estimated premorbid status predicts neurodegeneration in Alzheimer’s disease
This study investigated the relationship between premorbid and current cognitive function with respect to the clinical features of patients with various types of neurodegeneration in the form of Alzheimer’s disease (AD), mild cognitive impairment (MCI), and subjective cognitive impairment (SCI), as compared with a healthy control group (C). Clinical features (MMSE, cognitive and depressive symptoms), […]